Development of a Dual Energy CT Based Model to Assess Response to Treatment in Patients with High Grade Serous Ovarian Cancer: a Pilot Cohort Study

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2023 Jun 15

PMID 37322564

Authors

Zena Alizzi

Andrew Gogbashian

Emmanouil Karteris

Marcia Hall

Affiliations

Soon will be listed here.

Abstract

Background: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive disease, according to RECIST criteria. Dual Energy CT (DECT) permits additional measurements of iodine concentration, a surrogate marker of vascularity. Here we explore the role of changes in iodine concentration within cancer tissue on CT scans to assess its suitability for determining treatment response in patients with high grade serous ovarian cancer (HGSOC).

Methods: Suitable RECIST measurable lesions were identified from the CT images of HGSOC patients, taken at 2 different time points (pre and post treatment). Changes in size and iodine concentration were measured for each lesion. PR/SD were classified as responders, PD was classified as non-responder. Radiological responses were correlated with clinical and CA125 outcomes.

Results: 62 patients had appropriate imaging for assessment. 22 were excluded as they only had one DECT scan. 32/40 patients assessed (113 lesions) had received treatment for relapsed HGSOC. RECIST and GCIG (Gynaecologic Cancer Inter Group) CA125 criteria / clinical assessment of response for patients was correlated with changes in iodine concentration, before and after treatment. The prediction of median progression free survival was significantly better associated with changes in iodine concentration (p = 0.0001) and GCIG Ca125 / clinical assessment (p = 0.0028) in comparison to RECIST criteria (p = 0.43).

Conclusion: Changes in iodine concentration from dual energy CT imaging may be more suitable than RECIST in assessing response to treatment in patients with HGSOC.

Trial Registration: CICATRIx IRAS number 198179, 14 Dec 2015, https://www.myresearchproject.org.uk/ .

Citing Articles

Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.

Wiley N, Zecevic M, Ho V, Stolzberg M, Cox D, Soloff E Eur Radiol. 2025; .

PMID: 39873753 DOI: 10.1007/s00330-025-11351-4.

Current trends in the characterization and monitoring of vascular response to cancer therapy.

Shrestha B, Stern N, Zhou A, Dunn A, Porter T Cancer Imaging. 2024; 24(1):143.

PMID: 39438891 PMC: 11515715. DOI: 10.1186/s40644-024-00767-8.

Dual-energy CT in musculoskeletal imaging: technical considerations and clinical applications.

Albano D, Di Luca F, DAngelo T, Booz C, Midiri F, Gitto S Radiol Med. 2024; 129(7):1038-1047.

PMID: 38743319 PMC: 11252181. DOI: 10.1007/s11547-024-01827-6.

Dual-energy CT quantitative parameters to evaluate occult peritoneal metastasis in advanced gastric cancer preoperatively.

Feng Q, Zhu Z, Li Q, Liu X Abdom Radiol (NY). 2024; 49(10):3309-3318.

PMID: 38634880 DOI: 10.1007/s00261-024-04303-x.

References

Chen X, Ren K, Liang P, Chai Y, Chen K, Gao J . Spectral computed tomography in advanced gastric cancer: Can iodine concentration non-invasively assess angiogenesis?. World J Gastroenterol. 2017; 23(9):1666-1675. PMC: 5340819. DOI: 10.3748/wjg.v23.i9.1666. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Razi T, Niknami M, Alavi Ghazani F . Relationship between Hounsfield Unit in CT Scan and Gray Scale in CBCT. J Dent Res Dent Clin Dent Prospects. 2014; 8(2):107-10. PMC: 4120902. DOI: 10.5681/joddd.2014.019. View

Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L . ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer. 2021; 31(7):961-982. PMC: 8273689. DOI: 10.1136/ijgc-2021-002565. View

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Nougaret S, Tardieu M, Vargas H, Reinhold C, Vande Perre S, Bonanno N . Ovarian cancer: An update on imaging in the era of radiomics. Diagn Interv Imaging. 2018; 100(10):647-655. DOI: 10.1016/j.diii.2018.11.007. View

van Elmpt W, Landry G, Das M, Verhaegen F . Dual energy CT in radiotherapy: Current applications and future outlook. Radiother Oncol. 2016; 119(1):137-44. DOI: 10.1016/j.radonc.2016.02.026. View

Meyer M, Hohenberger P, Apfaltrer P, Henzler T, Dinter D, Schoenberg S . CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria. Eur J Radiol. 2013; 82(6):923-8. DOI: 10.1016/j.ejrad.2013.01.006. View

10.

Coursey C, Nelson R, Boll D, Paulson E, Ho L, Neville A . Dual-energy multidetector CT: how does it work, what can it tell us, and when can we use it in abdominopelvic imaging?. Radiographics. 2010; 30(4):1037-55. DOI: 10.1148/rg.304095175. View

11.

Lv P, Lin X, Li J, Li W, Chen K . Differentiation of small hepatic hemangioma from small hepatocellular carcinoma: recently introduced spectral CT method. Radiology. 2011; 259(3):720-9. DOI: 10.1148/radiol.11101425. View

12.

Thigpen J . Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecol Oncol. 2014; 136(1):121-9. DOI: 10.1016/j.ygyno.2014.10.010. View

13.

Guppy A, Rustin G . CA125 response: can it replace the traditional response criteria in ovarian cancer?. Oncologist. 2002; 7(5):437-43. DOI: 10.1634/theoncologist.7-5-437. View

14.

Ge X, Yu J, Wang Z, Xu Y, Pan C, Jiang L . Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer. BMC Cancer. 2018; 18(1):1120. PMC: 6240303. DOI: 10.1186/s12885-018-5058-2. View

15.

Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E . Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):928-36. PMC: 4648090. DOI: 10.1016/S1470-2045(15)00086-8. View

16.

Choi H, Charnsangavej C, Faria S, Macapinlac H, Burgess M, Patel S . Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25(13):1753-9. DOI: 10.1200/JCO.2006.07.3049. View

17.

Rustin G, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T . Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21(2):419-23. DOI: 10.1097/IGC.0b013e3182070f17. View

18.

Kawamoto S, Fuld M, Laheru D, Huang P, Fishman E . Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT. Abdom Radiol (NY). 2018; 43(2):445-456. PMC: 7385923. DOI: 10.1007/s00261-017-1338-6. View

19.

Dudeck O, Zeile M, Reichardt P, Pink D . Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2011; 22(8):1828-33. DOI: 10.1093/annonc/mdq696. View

20.

Chen Y, Yuan F, Wang L, Li E, Xu Z, Wels M . Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy. Eur J Surg Oncol. 2021; 48(2):339-347. DOI: 10.1016/j.ejso.2021.07.014. View